Pasusant Wattanaboonya is a Thai chronic myeloid leukemia (CML) patient and advocate who has been living with CML for over 26 years.

Diagnosed at the age of 35, he has undergone various treatments, including hydroxyurea, subcutaneous injections, and targeted therapy through the Glivec International Patient Assistance Program (GIPAP). Since September 2018, due to the effectiveness of targeted therapy and positive molecular responses, he has ceased medication and participates in a clinical trial program involving regular molecular monitoring.

Professionally, after graduating from commercial college, Pasusant worked for multinational companies and currently engages in freelance work. He volunteers as a committee member of the Thai CML Patient Group and is the founder of the MPN Patient Advocacy Group Thailand. His advocacy efforts focus on educating himself and others about blood cancers, providing support to patients and caregivers, and raising funds for destitute cancer patients through personal projects and social media initiatives.

Pasusant’s dedication to patient advocacy is further demonstrated by his role as a steering committee member of the Acute Leukemia Advocates Network (ALAN), where he collaborates with international organizations to support leukemia patients globally.

His journey from a CML patient to a prominent advocate highlights his commitment to improving the lives of cancer patients in Thailand and beyond.

.